Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Prothena Corporation plc (PRTA)
USD8.58
-0.06 (-0.66%)
IE NASDAQ Healthcare Biotechnology
Address
77 Sir John Rogerson’s Quay D02 VK60
Dublin, DU, IE
Dublin, DU, IE
CEO
Gene G. Kinney
Website
prothena.com
IPO
2012-12-20
CIK 1559053 ISIN IE00B91XRN20
Description
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
News Sentiment (7d)
Based on only 1 article — low confidence
- PRTA Stock Rises Nearly 11% in Six Months: What's Driving It? Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD8.58
-0.06 (-0.66%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
534.7K
Beta
-0.32
Float Shares
43.33M
Free Float %
80.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.48% | -14.27% | -8.54% | +5.25% | -7.37% | -1.26% | +24.24% | -87.42% | -56.40% | -76.82% | +30.97% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (28 ratings, all time)
Buy
Price Targets & DCF
Current price
8.58
Low
19.00
+121.4%
Consensus
19.00
+121.4%
Median
19.00
+121.4%
High
19.00
+121.4%
DCF (Unlevered)
3.35
-60.9%
DCF (Levered)
3.19
-62.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
50% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 1 | -1 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
19.00
+121.4%
|
| Last Year | 7 |
22.86
+166.3%
|
| All Time | 14 |
41.71
+385.9%
|
Quality scores
Altman Z-Score
3.32
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-92.8% Q1'26: +1,706.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-99.6% Q1'26: +153.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-2,526.9% Q1'26: +56.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-2,073.8% Q1'26: +50.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: -1,122.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.1% ★ Q1'26: +0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.07× Q1'26: 0.07× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 2 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 4 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
Dec 2030 1 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.61M
est: 1.79M (-10.5%)
|
1.06M
est: 1.15M (-7.9%)
|
27.52M
est: 27.57M (-0.2%)
|
955.0K
est: 955.0K (+0.0%)
|
814.0K
est: 859.3K (-5.3%)
|
853.0K
est: 649.2K (+31.4%)
|
200.58M
est: 205.49M (-2.4%)
|
53.91M
est: 43.01M (+25.3%)
|
91.37M
est: 217.25M (-57.9%)
|
135.16M
est: 140.55M (-3.8%)
|
9.68M
est: 10.84M (-10.6%)
|
83.32M
68.60M – 98.03M
+668.8% YoY
|
26.40M
22.38M – 31.32M
-68.3% YoY
|
134.77M
114.22M – 159.90M
+410.5% YoY
|
200.54M
169.97M – 237.92M
+48.8% YoY
|
265.60M
225.11M – 315.12M
+32.4% YoY
|
| EBITDA |
-79.13M
est: -78.23M (-1.1%)
|
-156.54M
est: -129.60M (-20.8%)
|
-152.19M
est: -176.09M (+13.6%)
|
-152.90M
est: -123.49M (-23.8%)
|
-84.19M
est: -78.56M (-7.2%)
|
-111.22M
est: -94.98M (-17.1%)
|
73.09M
est: 91.49M (-20.1%)
|
-130.81M
est: 21.43M (-710.4%)
|
-190.11M
est: -157.96M (-20.3%)
|
-153.67M
est: -102.20M (-50.4%)
|
-197.13M
est: -7.88M (-2,401.5%)
|
-60.58M
-71.28M – -49.88M
-668.8% YoY
|
-19.20M
-22.77M – -16.27M
+68.3% YoY
|
-97.99M
-116.26M – -83.06M
-410.5% YoY
|
-145.81M
-173.00M – -123.59M
-48.8% YoY
|
-193.12M
-229.13M – -163.68M
-32.4% YoY
|
| EBIT |
-79.94M
est: -79.08M (-1.1%)
|
-158.96M
est: -132.04M (-20.4%)
|
-153.92M
est: -180.11M (+14.5%)
|
-152.42M
est: -133.09M (-14.5%)
|
-85.76M
est: -97.83M (+12.3%)
|
-112.73M
est: -103.98M (-8.4%)
|
71.98M
est: 85.07M (-15.4%)
|
-131.56M
est: 13.34M (-1,086.5%)
|
-191.04M
est: -158.21M (-20.8%)
|
-154.56M
est: -102.35M (-51.0%)
|
-200.83M
est: -7.89M (-2,444.6%)
|
-60.68M
-71.39M – -49.96M
-668.8% YoY
|
-19.23M
-22.81M – -16.29M
+68.3% YoY
|
-98.14M
-116.44M – -83.18M
-410.5% YoY
|
-146.04M
-173.26M – -123.77M
-48.8% YoY
|
-193.42M
-229.48M – -163.93M
-32.4% YoY
|
| Net Income |
-80.61M
est: -79.72M (-1.1%)
|
-160.11M
est: -132.60M (-20.7%)
|
-153.24M
est: -177.75M (+13.8%)
|
-155.65M
est: -130.92M (-18.9%)
|
-77.68M
est: -88.48M (+12.2%)
|
-111.14M
est: -102.52M (-8.4%)
|
66.98M
est: 81.38M (-17.7%)
|
-116.95M
est: 16.03M (-829.5%)
|
-147.03M
est: -50.92M (-188.7%)
|
-122.31M
est: -111.22M (-10.0%)
|
-244.09M
est: -254.61M (+4.1%)
|
2.76M
-968.9K – 6.50M
+101.1% YoY
|
-36.40M
-68.64M – -33.66M
-1,417.4% YoY
|
1.36M
-31.10M – 36.07M
+103.7% YoY
|
-9.29M
-11.54M – -7.45M
-783.3% YoY
|
124.34M
99.70M – 154.48M
+1,439.1% YoY
|
| SGA |
23.11M
est: 17.12M (+34.9%)
|
41.06M
est: 10.93M (+275.5%)
|
48.23M
est: 263.01M (-81.7%)
|
42.48M
est: 9.11M (+366.3%)
|
35.74M
est: 8.20M (+335.9%)
|
38.70M
est: 6.19M (+524.9%)
|
46.32M
est: 44.10M (+5.0%)
|
49.90M
est: 42.64M (+17.0%)
|
61.84M
est: 367.74M (-83.2%)
|
67.20M
est: 237.91M (-71.8%)
|
59.39M
est: 18.34M (+223.8%)
|
141.04M
116.12M – 165.94M
+668.8% YoY
|
44.69M
37.88M – 53.02M
-68.3% YoY
|
228.13M
193.35M – 270.66M
+410.5% YoY
|
339.45M
287.70M – 402.74M
+48.8% YoY
|
449.58M
381.05M – 533.40M
+32.4% YoY
|
| EPS |
-2.66
est: -2.70 (+1.5%)
|
-4.66
est: -4.39 (-6.2%)
|
-4.07
est: -4.23 (+3.7%)
|
-3.93
est: -4.31 (+8.8%)
|
-1.95
est: -1.98 (+1.4%)
|
-2.78
est: -2.79 (+0.3%)
|
1.51
est: 1.31 (+15.2%)
|
-2.47
est: -3.02 (+18.3%)
|
-2.76
est: -0.95 (-190.9%)
|
-2.27
est: -2.21 (-2.5%)
|
-4.53
est: -4.69 (+3.5%)
|
0.05
-0.02 – 0.12
+101.0% YoY
|
-1.03
-1.28 – -0.63
-2,307.1% YoY
|
0.17
-0.58 – 0.67
+116.3% YoY
|
-0.17
-0.21 – -0.14
-203.0% YoY
|
2.31
1.85 – 2.87
+1,439.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-103.11M
OE per share TTM
-1.92
Owner's Yield
-18.25%
Maintenance CapEx ratio
32.86%
Maint CapEx / Avg PPE
22.3%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
36
Total invested
16.69M
Insider transactions (90d)
0
Beneficial owners (>5%)
34
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | T. ROWE PRICE ASSOCIATES, INC. | 14.72M | 7.00% | 1.61M | — | 1.67M | — | IA | Delaware | 2015-02-02 | ↗ |
| 2 | Woodford Equity Income Fund | 7.68M | 20.00% | — | 7.68M | — | — | FI | Kingdom | 2018-02-13 | ↗ |
| 3 | Jeremy Mindich | 4.62M | 11.60% | — | 4.62M | — | 4.62M | HC, IN | United States | 2019-01-10 | ↗ |
| 4 | Matthew Sirovich | 4.62M | 11.60% | — | 4.62M | — | 4.62M | HC, IN | United States | 2019-01-10 | ↗ |
| 5 | Scopia Capital Management LP | 4.62M | 11.60% | — | 4.62M | — | 4.62M | IA, PN | United States | 2019-01-10 | ↗ |
| 6 | Scopia Management, Inc. | 4.62M | 11.60% | — | 4.62M | — | 4.62M | HC, CO | United States | 2019-01-10 | ↗ |
| 7 | Wellington Group Holdings LLP | 4.18M | 7.77% | — | 4.12M | — | — | HC | Massachusetts | 2024-11-08 | ↗ |
| 8 | Wellington Investment Advisors Holdings LLP | 4.18M | 7.77% | — | 4.12M | — | — | HC | Massachusetts | 2024-11-08 | ↗ |
| 9 | Wellington Management Group LLP | 4.18M | 7.77% | — | 4.12M | — | — | HC | Massachusetts | 2024-11-08 | ↗ |
| 10 | Wellington Management Company LLP | 4.15M | 7.71% | — | 4.12M | — | — | IA | Massachusetts | 2024-11-08 | ↗ |
| 11 | William P. Scully | 3.50M | 6.53% | 349.0K | 3.15M | 349.0K | — | IN | Florida | 2024-02-14 | ↗ |
| 12 | Elan Corporation Limited | 3.18M | 14.56% | — | — | — | 3.18M | CO | Ireland | 2014-01-28 | ↗ |
| 13 | Elan Science One Limited | 3.18M | 14.56% | — | — | — | 3.18M | CO | Ireland | 2014-01-28 | ↗ |
| 14 | Perrigo Company plc | 3.18M | 14.56% | — | — | — | 3.18M | CO | Ireland | 2014-01-28 | ↗ |
| 15 | Todd W. Fennell | 3.14M | 5.85% | — | 3.14M | — | 3.14M | IN | Florida | 2024-02-14 | ↗ |
| 16 | Woodford Investment Management LLP | 3.14M | 10.30% | — | 3.14M | — | — | PN | United Kingdom | 2015-02-26 | ↗ |
| 17 | CF Woodford Equity Income Fund | 3.02M | 11.00% | — | 3.02M | — | — | OO | United Kingdom | 2015-04-07 | ↗ |
| 18 | 52-0556948 | 3.01M | 6.40% | 556.0K | — | 3.01M | — | IA | Maryland | 2022-08-10 | ↗ |
| 19 | STATE STREET CORPORATION | 2.76M | 5.14% | — | 2.64M | — | 2.76M | HC | BOSTON, MASSACHUSETTS | 2024-01-24 | ↗ |
| 20 | Patient Capital Trust | 2.55M | 6.60% | — | 2.55M | — | — | FI | United Kingdom | 2018-02-13 | ↗ |
| 21 | Patient Capital Trust Plc | 2.48M | 6.20% | — | 2.48M | — | 2.48M | FI | Kingdom | 2019-02-14 | ↗ |
| 22 | OrbiMed Capital LLC | 2.29M | 5.74% | — | 2.29M | — | — | IA | Delaware | 2020-02-14 | ↗ |
| 23 | Mr. David Kroin | 2.07M | 5.18% | — | 2.07M | — | 2.07M | IN | USA | 2019-08-05 | ↗ |
| 24 | First Light Asset Management, LLC | 1.81M | 3.87% | — | 1.81M | — | — | IA | Delaware | 2022-03-01 | ↗ |
| 25 | Mathew P. Arens | 1.81M | 3.87% | — | 1.81M | — | — | IN | Delaware | 2022-03-01 | ↗ |
| 26 | Peter Kolchinsky | 1.65M | 9.30% | — | 1.65M | — | 1.65M | IN | Massachusetts | 2013-08-27 | ↗ |
| 27 | RA Capital Management, LLC | 1.65M | 9.30% | — | 1.65M | — | 1.65M | IA | Massachusetts | 2013-08-27 | ↗ |
| 28 | NAME OF REPORTING | 1.20M | 5.50% | — | 413.5K | — | 413.5K | HC | Delaware | 2014-02-13 | ↗ |
| 29 | Dr. Jeffrey R. Jay, M.D. | 977.6K | 2.45% | — | 977.6K | — | — | HC, IN | USA | 2021-02-16 | ↗ |
| 30 | Great Point Partners, LLC | 977.6K | 2.45% | — | 977.6K | — | — | IA, OO | USA | 2021-02-16 | ↗ |
| 31 | Mr. Ortav Yehudai | 977.6K | 2.45% | — | 977.6K | — | — | HC, IN | USA | 2021-02-16 | ↗ |
| 32 | Advisors LLC | 613.8K | 1.54% | — | 613.8K | — | — | IA | Delaware | 2020-02-14 | ↗ |
| 33 | Jennison Associates LLC | 378.00 | 0.00% | 209.4K | — | 209.4K | — | IA | New Jersey | 2013-10-10 | ↗ |
| 34 | BRONCO (BARCLAYS CAYMAN) LIMITED | — | 0.00% | 1.66M | — | — | — | — | Delaware For | 2015-02-06 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
36
-157 vs prev Q
New positions
5
Closed positions
149
Increased
16
Reduced
6
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | FMR LLC | 7.55M -350.0K (-4.4%) | 72.11M -5.0M (-6.5%) | 14.03% -0.651 pp | 0.00% 0.000 pp | USD44.89 -78.7% | 52 qtrs — |
| 2 | BLACKROCK, INC. | 4.11M +509.0K (+14.1%) | 39.23M +4.1M (+11.7%) | 7.63% +0.945 pp | 0.00% +0.000 pp | USD15.78 -39.5% | 6 qtrs — |
| 3 | RUBRIC CAPITAL MANAGEMENT LP | 3.68M +2.1M (+138.7%) | 35.12M +20.1M (+133.6%) | 6.83% +3.970 pp | 0.42% +0.250 pp | USD9.64 -0.9% | 2 qtrs — |
| 4 | STATE STREET CORP | 2.27M +1.4M (+151.7%) | 21.66M +12.9M (+146.3%) | 4.21% +2.539 pp | 0.00% +0.000 pp | USD19.14 -50.1% | 51 qtrs — |
| 5 | VANGUARD GROUP INC | 2.14M +91.1K (+4.4%) | 20.45M +439.2K (+2.2%) | 3.98% +0.169 pp | 0.00% +0.000 pp | USD23.67 -59.7% | 51 qtrs — |
| 6 | D. E. SHAW & CO., INC. | 1.68M +366.0K (+27.8%) | 16.06M +3.2M (+25.1%) | 3.12% +0.680 pp | 0.01% +0.002 pp | USD8.92 +7.1% | 4 qtrs — |
| 7 | ARMISTICE CAPITAL, LLC | 1.50M -324.0K (-17.8%) | 14.33M -3.5M (-19.5%) | 2.79% -0.602 pp | 0.17% -0.094 pp | USD22.34 -57.3% | 9 qtrs — |
| 8 | ADAR1 CAPITAL MANAGEMENT, LLC | 1.46M -11.3K (-0.8%) | 13.92M -416.8K (-2.9%) | 2.71% -0.021 pp | 1.02% -0.324 pp | USD6.07 +57.3% | 3 qtrs — |
| 9 | ACADIAN ASSET MANAGEMENT LLC | 1.44M +198.1K (+16.0%) | 13.72M +1.6M (+13.5%) | 2.67% +0.368 pp | 0.02% +0.001 pp | USD7.12 +34.1% | 5 qtrs — |
| 10 | PALO ALTO INVESTORS LP | 1.32M -3.5K (-0.3%) | 12.61M -311.6K (-2.4%) | 2.45% -0.007 pp | 1.76% -0.636 pp | USD21.13 -54.8% | 51 qtrs — |
| 11 | MORGAN STANLEY | 1.25M +447.1K (+55.9%) | 11.91M +4.1M (+52.6%) | 2.32% +0.831 pp | 0.00% +0.000 pp | USD21.12 -54.8% | 51 qtrs — |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 1.06M +43.6K (+4.3%) | 10.15M +202.0K (+2.0%) | 1.97% +0.081 pp | 0.00% +0.000 pp | USD33.96 -71.9% | 51 qtrs — |
| 13 | JACOBS LEVY EQUITY MANAGEMENT, INC | 978.0K +101.5K (+11.6%) | 9.34M +785.1K (+9.2%) | 1.82% +0.188 pp | 0.04% +0.002 pp | USD7.24 +31.9% | 4 qtrs — |
| 14 | FEDERATED HERMES, INC. | 974.4K +281.5K (+40.6%) | 9.31M +2.5M (+37.6%) | 1.81% +0.523 pp | 0.02% +0.004 pp | USD10.22 -6.6% | 7 qtrs — |
| 15 | GOLDMAN SACHS GROUP INC | 935.3K +582.1K (+164.8%) | 8.93M +5.5M (+159.1%) | 1.74% +1.081 pp | 0.00% +0.001 pp | USD16.75 -43.0% | 51 qtrs — |
| 16 | CITADEL ADVISORS LLC | 912.4K +145.3K (+18.9%) | 8.71M +1.2M (+16.4%) | 1.69% +0.270 pp | 0.00% +0.000 pp | USD7.66 +24.7% | 38 qtrs — |
| 17 | POINT72 ASSET MANAGEMENT, L.P. | 860.0K +213.3K (+33.0%) | 8.21M +1.9M (+30.1%) | 1.60% +0.396 pp | 0.01% -0.001 pp | USD9.71 -1.6% | 2 qtrs — |
| 18 | DIMENSIONAL FUND ADVISORS LP | 775.2K -31.8K (-3.9%) | 7.40M -473.3K (-6.0%) | 1.44% -0.059 pp | 0.00% 0.000 pp | USD12.45 -23.3% | 31 qtrs — |
| 19 | NUVEEN, LLC | 759.1K +90.8K (+13.6%) | 7.25M +727.0K (+11.1%) | 1.41% +0.169 pp | 0.00% +0.000 pp | USD10.16 -6.0% | 4 qtrs — |
| 20 | TWO SIGMA INVESTMENTS, LP | 670.1K +243.5K (+57.1%) | 6.40M +2.2M (+53.7%) | 1.24% +0.452 pp | 0.01% +0.003 pp | USD8.80 +8.5% | 7 qtrs — |
| 21 | MARINER, LLC | 577.9K -13.0K (-2.2%) | 5.52M -248.0K (-4.3%) | 1.07% -0.024 pp | 0.01% -0.001 pp | USD23.90 -60.0% | 17 qtrs — |
| 22 | RANGELEY CAPITAL, LLC | 524.6K -35.9K (-6.4%) | 5.01M -460.1K (-8.4%) | 0.97% -0.067 pp | 4.16% -0.572 pp | USD6.07 +57.3% | 3 qtrs — |
| 23 | BIRCHVIEW CAPITAL, LP | 441.0K -108.0K (-19.7%) | 4.21M -1.1M (-21.4%) | 0.82% -0.201 pp | 2.47% -1.580 pp | USD22.23 -57.0% | 19 qtrs — |
| 24 | RENAISSANCE TECHNOLOGIES LLC | 435.5K +64.2K (+17.3%) | 4.16M +535.3K (+14.8%) | 0.81% +0.119 pp | 0.01% +0.002 pp | USD12.63 -24.4% | 30 qtrs — |
| 25 | TWO SIGMA ADVISERS, LP | 427.4K +161.7K (+60.9%) | 4.08M +1.5M (+57.4%) | 0.79% +0.300 pp | 0.01% +0.003 pp | USD8.47 +12.8% | 3 qtrs — |
| 26 | BANK OF AMERICA CORP /DE/ | 427.4K +150.3K (+54.2%) | 4.08M +1.4M (+50.9%) | 0.79% +0.279 pp | 0.00% +0.000 pp | USD15.52 -38.5% | 52 qtrs — |
| 27 | UBS GROUP AG | 426.4K +25.5K (+6.4%) | 4.07M +159.5K (+4.1%) | 0.79% +0.047 pp | 0.00% +0.000 pp | USD10.75 -11.2% | 45 qtrs — |
| 28 | BNP PARIBAS ARBITRAGE, SNC | 424.0K +195.9K (+85.9%) | 4.05M +1.8M (+81.9%) | 0.79% +0.364 pp | 0.00% +0.001 pp | USD9.72 -1.7% | 49 qtrs — |
| 29 | QUBE RESEARCH & TECHNOLOGIES LTD | 407.7K +153.4K (+60.4%) | 3.89M +1.4M (+56.9%) | 0.76% +0.285 pp | 0.00% +0.001 pp | USD7.38 +29.4% | 3 qtrs — |
| 30 | NORTHERN TRUST CORP | 363.2K +28.6K (+8.5%) | 3.47M +202.7K (+6.2%) | 0.67% +0.053 pp | 0.00% +0.000 pp | USD34.25 -72.1% | 51 qtrs — |
| 31 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 357.3K +6.5K (+1.9%) | 3.41M -11.5K (-0.3%) | 0.66% +0.012 pp | 0.00% +0.000 pp | USD35.05 -72.8% | 51 qtrs — |
| 32 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 312.5K -427.8K (-57.8%) | 2.98M -4.2M (-58.7%) | 0.58% -0.795 pp | 0.00% -0.001 pp | USD8.21 +16.3% | 49 qtrs — |
| 33 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 298.1K -356.2K (-54.4%) | 2.85M -3.5M (-55.4%) | 0.55% -0.662 pp | 0.00% -0.002 pp | USD9.76 -2.2% | 2 qtrs — |
| 34 | MAN GROUP PLC | 269.5K +137.5K (+104.2%) | 2.57M +1.3M (+99.8%) | 0.50% +0.256 pp | 0.00% +0.002 pp | USD10.22 -6.6% | 15 qtrs — |
| 35 | MONIMUS CAPITAL MANAGEMENT, LP | 254.1K -3.9K (-1.5%) | 2.43M -91.8K (-3.6%) | 0.47% -0.007 pp | 1.60% +0.049 pp | USD6.81 +40.2% | 3 qtrs — |
| 36 | JUMP FINANCIAL, LLC | 237.8K +51.6K (+27.7%) | 2.27M +453.5K (+24.9%) | 0.44% +0.096 pp | 0.03% +0.006 pp | USD9.71 -1.6% | 2 qtrs — |
| 37 | SQUAREPOINT OPS LLC | 218.0K +91.0K (+71.6%) | 2.08M +842.5K (+67.9%) | 0.41% +0.169 pp | 0.00% +0.001 pp | USD7.52 +27.0% | 3 qtrs — |
| 38 | DCF ADVISERS, LLC | 195.7K -5.0K (-2.5%) | 1.87M -89.9K (-4.6%) | 0.36% -0.009 pp | 0.50% -0.128 pp | USD20.98 -54.5% | 20 qtrs — |
| 39 | AQR CAPITAL MANAGEMENT LLC | 186.8K -27.8K (-12.9%) | 1.78M -310.1K (-14.8%) | 0.35% -0.052 pp | 0.00% 0.000 pp | USD9.76 -2.2% | 2 qtrs — |
| 40 | BARCLAYS PLC | 183.6K +88.4K (+92.8%) | 1.75M +160.6K (+10.1%) | 0.34% +0.164 pp | 0.00% +0.000 pp | USD16.87 -43.4% | 51 qtrs — |
| 41 | JPMORGAN CHASE & CO | 170.0K -565.8K (-76.9%) | 1.62M -5.6M (-77.4%) | 0.32% -1.051 pp | 0.00% 0.000 pp | USD13.93 -31.4% | 45 qtrs — |
| 42 | WALLEYE CAPITAL LLC | 156.0K +156.0K (+247,574.6%) | 1.49M +1.5M (+242,198.2%) | 0.29% +0.290 pp | 0.00% +0.005 pp | USD9.55 +0.0% | 11 qtrs — |
| 43 | JANE STREET GROUP, LLC | 136.1K -42.8K (-23.9%) | 1.30M -446.3K (-25.6%) | 0.25% -0.080 pp | 0.00% 0.000 pp | USD6.81 +40.2% | 3 qtrs — |
| 44 | BANK OF NEW YORK MELLON CORP | 132.7K -21.1K (-13.7%) | 1.27M -233.8K (-15.6%) | 0.25% -0.039 pp | 0.00% 0.000 pp | USD45.88 -79.2% | 51 qtrs — |
| 45 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 125.9K +125.9K (+100.0%) | 1.20M +1.2M (+100.0%) | 0.23% +0.234 pp | 0.00% +0.003 pp | USD9.55 +0.0% | 15 qtrs — |
| 46 | FOCUSED WEALTH MANAGEMENT, INC | 107.5K +50.4K (+88.1%) | 1.03M +468.8K (+84.1%) | 0.20% +0.094 pp | 0.11% +0.048 pp | USD10.88 -12.2% | 44 qtrs — |
| 47 | DIADEMA PARTNERS LP | 106.5K +106.5K (+100.0%) | 1.02M +1.0M (+100.0%) | 0.20% +0.198 pp | 0.18% +0.175 pp | USD9.55 +0.0% | 1 qtrs NEW |
| 48 | AMERIPRISE FINANCIAL INC | 105.4K -95.0 (-0.1%) | 1.01M -23.1K (-2.2%) | 0.20% 0.000 pp | 0.00% +0.000 pp | USD6.07 +57.3% | 3 qtrs — |
| 49 | LOS ANGELES CAPITAL MANAGEMENT LLC | 95.4K -24.0K (-20.1%) | 999.9K -165.7K (-14.2%) | 0.18% -0.045 pp | 0.00% -0.001 pp | USD9.24 +3.4% | 3 qtrs — |
| 50 | QUANTINNO CAPITAL MANAGEMENT LP | 103.6K +2.4K (+2.4%) | 989.6K +2.0K (+0.2%) | 0.19% +0.005 pp | 0.00% -0.001 pp | USD7.63 +25.2% | 3 qtrs — |
| 51 | Y-INTERCEPT (HONG KONG) LTD | 100.5K +88.3K (+725.8%) | 959.9K +841.1K (+708.0%) | 0.19% +0.164 pp | 0.02% +0.019 pp | USD9.58 -0.3% | 2 qtrs — |
| 52 | CAPTION MANAGEMENT, LLC | 100.0K +— (+0.0%) | 955.0K -21.0K (-2.2%) | 0.19% +0.000 pp | 0.01% -0.001 pp | USD6.07 +57.3% | 3 qtrs — |
| 53 | RUSSELL INVESTMENTS GROUP, LTD. | 99.4K -28.4K (-22.2%) | 948.8K -298.1K (-23.9%) | 0.18% -0.053 pp | 0.00% 0.000 pp | USD7.10 +34.5% | 9 qtrs — |
| 54 | CAMPBELL & CO INVESTMENT ADVISER LLC | 94.2K +94.2K (+100.0%) | 899.2K +899.2K (+100.0%) | 0.17% +0.175 pp | 0.04% +0.043 pp | USD9.55 +0.0% | 1 qtrs NEW |
| 55 | HENNION & WALSH ASSET MANAGEMENT, INC. | 91.3K +6.7K (+7.9%) | 871.8K +46.1K (+5.6%) | 0.17% +0.012 pp | 0.03% +0.000 pp | USD12.42 -23.1% | 5 qtrs — |
| 56 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 88.0K +57.7K (+190.8%) | 840.3K +545.0K (+184.6%) | 0.16% +0.107 pp | 0.01% +0.004 pp | USD9.87 -3.2% | 4 qtrs — |
| 57 | RAFFERTY ASSET MANAGEMENT, LLC | 82.6K +82.6K (+100.0%) | 788.4K +788.4K (+100.0%) | 0.15% +0.153 pp | 0.00% +0.003 pp | USD9.55 +0.0% | 1 qtrs NEW |
| 58 | PRICE T ROWE ASSOCIATES INC /MD/ | 81.5K +3.0K (+3.8%) | 779.0K +12.0K (+1.6%) | 0.15% +0.006 pp | 0.00% +0.000 pp | USD37.69 -74.7% | 22 qtrs — |
| 59 | AMERICAN CENTURY COMPANIES INC | 78.8K +6.6K (+9.1%) | 752.6K +47.5K (+6.7%) | 0.15% +0.012 pp | 0.00% +0.000 pp | USD10.96 -12.9% | 6 qtrs — |
| 60 | MILLENNIUM MANAGEMENT LLC | 77.4K +77.4K (+100.0%) | 739.2K +739.2K (+100.0%) | 0.14% +0.144 pp | 0.00% +0.000 pp | USD9.55 +0.0% | 1 qtrs NEW |
| 61 | ASSENAGON ASSET MANAGEMENT S.A. | 76.8K -12.9K (-14.4%) | 733.1K -142.4K (-16.3%) | 0.14% -0.024 pp | 0.00% 0.000 pp | USD9.76 -2.2% | 2 qtrs — |
| 62 | ALLIANCEBERNSTEIN L.P. | 69.6K +— (+0.0%) | 664.7K -14.6K (-2.2%) | 0.13% +0.000 pp | 0.00% +0.000 pp | USD31.51 -69.7% | 51 qtrs — |
| 63 | DUNCAN WILLIAMS ASSET MANAGEMENT, LLC | 70.3K -18.1K (-20.4%) | 624.8K -237.4K (-27.5%) | 0.13% -0.034 pp | 0.16% -0.087 pp | USD15.12 -36.8% | 6 qtrs — |
| 64 | MARTINGALE ASSET MANAGEMENT L P | 63.5K +63.5K (+100.0%) | 606.0K +606.0K (+100.0%) | 0.12% +0.118 pp | 0.02% +0.015 pp | USD9.55 +0.0% | 1 qtrs NEW |
| 65 | SG AMERICAS SECURITIES, LLC | 63.0K +6.3K (+11.1%) | 602.0K +48.0K (+8.7%) | 0.12% +0.012 pp | 0.00% -0.001 pp | USD14.77 -35.3% | 25 qtrs — |
| 66 | PINNACLE ASSOCIATES LTD | 62.7K -8.5K (-12.0%) | 599.0K -96.5K (-13.9%) | 0.12% -0.016 pp | 0.01% -0.002 pp | USD34.20 -72.1% | 41 qtrs — |
| 67 | CREATIVE PLANNING | 62.0K -2.2K (-3.4%) | 591.8K -34.2K (-5.5%) | 0.12% -0.004 pp | 0.00% 0.000 pp | USD8.63 +10.7% | 8 qtrs — |
| 68 | WELLS FARGO & COMPANY/MN | 60.1K +19.7K (+48.7%) | 574.0K +179.4K (+45.5%) | 0.11% +0.037 pp | 0.00% +0.000 pp | USD32.42 -70.5% | 52 qtrs — |
| 69 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 58.9K +29.9K (+103.1%) | 562.0K +279.3K (+98.7%) | 0.11% +0.056 pp | 0.01% +0.004 pp | USD7.84 +21.8% | 3 qtrs — |
| 70 | RHUMBLINE ADVISERS | 56.5K -5.5K (-8.9%) | 539.8K -65.7K (-10.9%) | 0.11% -0.010 pp | 0.00% +0.000 pp | USD31.41 -69.6% | 51 qtrs — |
| 71 | XTX TOPCO LTD | 54.9K +39.1K (+247.2%) | 524.1K +369.8K (+239.7%) | 0.10% +0.073 pp | 0.01% +0.006 pp | USD9.61 -0.6% | 2 qtrs — |
| 72 | MARSHALL WACE, LLP | 54.8K +54.8K (+100.0%) | 523.1K +523.1K (+100.0%) | 0.10% +0.102 pp | 0.00% +0.001 pp | USD9.55 +0.0% | 1 qtrs NEW |
| 73 | QUINN OPPORTUNITY PARTNERS LLC | 50.0K +— (+0.0%) | 477.5K -10.5K (-2.2%) | 0.09% +0.000 pp | 0.02% -0.014 pp | USD6.07 +57.3% | 3 qtrs — |
| 74 | FRANKLIN RESOURCES INC | 47.3K -13.9K (-22.8%) | 451.2K -145.8K (-24.4%) | 0.09% -0.026 pp | 0.00% +0.000 pp | USD8.89 +7.4% | 5 qtrs — |
| 75 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 46.0K -1.5K (-3.2%) | 439.0K -24.5K (-5.3%) | 0.09% -0.003 pp | 0.00% +0.000 pp | USD13.49 -29.2% | 5 qtrs — |
| 76 | — | 43.3K +43.3K (+100.0%) | 413.5K +413.5K (+100.0%) | 0.08% +0.080 pp | 0.31% +0.315 pp | USD9.55 +0.0% | 1 qtrs NEW |
| 77 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 42.2K +— (+0.0%) | 402.6K -8.9K (-2.2%) | 0.08% +0.000 pp | 0.00% 0.000 pp | USD6.07 +57.3% | 3 qtrs — |
| 78 | DEUTSCHE BANK AG\ | 35.5K +1.7K (+5.1%) | 338.9K +9.2K (+2.8%) | 0.07% +0.003 pp | 0.00% +0.000 pp | USD20.33 -53.0% | 50 qtrs — |
| 79 | QUADRATURE CAPITAL LTD | 31.1K +3.9K (+14.2%) | 296.9K +31.6K (+11.9%) | 0.06% +0.007 pp | 0.00% 0.000 pp | USD6.91 +38.2% | 3 qtrs — |
| 80 | PROFUND ADVISORS LLC | 30.6K +30.6K (+100.0%) | 292.4K +292.4K (+100.0%) | 0.06% +0.057 pp | 0.01% +0.009 pp | USD9.55 +0.0% | 1 qtrs NEW |
| 81 | RBF CAPITAL, LLC | 29.2K +— (+0.0%) | 278.9K -6.1K (-2.2%) | 0.05% +0.000 pp | 0.01% 0.000 pp | USD23.25 -58.9% | 25 qtrs — |
| 82 | PERSISTENT ASSET PARTNERS LTD | 28.6K +28.6K (+100.0%) | 273.0K +273.0K (+100.0%) | 0.05% +0.053 pp | 0.12% +0.123 pp | USD9.55 +0.0% | 1 qtrs NEW |
| 83 | PNC FINANCIAL SERVICES GROUP, INC. | 28.1K +10.0K (+55.1%) | 268.6K +91.6K (+51.7%) | 0.05% +0.019 pp | 0.00% +0.000 pp | USD7.70 +24.0% | 23 qtrs — |
| 84 | GRAHAM CAPITAL MANAGEMENT, L.P. | 27.8K -25.6K (-48.0%) | 265.1K -256.0K (-49.1%) | 0.05% -0.048 pp | 0.01% -0.002 pp | USD7.41 +28.9% | 3 qtrs — |
| 85 | HSBC HOLDINGS PLC | 27.7K -9.7K (-25.9%) | 260.7K -103.9K (-28.5%) | 0.05% -0.018 pp | 0.00% 0.000 pp | USD8.79 +8.6% | 6 qtrs — |
| 86 | INVESCO LTD. | 26.6K -4.7K (-15.0%) | 254.1K -51.4K (-16.8%) | 0.05% -0.009 pp | 0.00% +0.000 pp | USD46.60 -79.5% | 53 qtrs — |
| 87 | TUDOR INVESTMENT CORP ET AL | 26.5K -600.0 (-2.2%) | 252.8K -11.4K (-4.3%) | 0.05% -0.001 pp | 0.00% +0.000 pp | USD6.07 +57.3% | 9 qtrs — |
| 88 | GSA CAPITAL PARTNERS LLP | 26.4K +26.4K (+100.0%) | 252.0K +252.0K (+100.0%) | 0.05% +0.049 pp | 0.02% +0.022 pp | USD9.55 +0.0% | 3 qtrs — |
| 89 | VIRTUS INVESTMENT ADVISERS, INC. | 25.7K +3.2K (+14.4%) | 245.2K +26.2K (+12.0%) | 0.05% +0.006 pp | 0.07% +0.004 pp | USD9.99 -4.4% | 4 qtrs — |
| 90 | METLIFE INVESTMENT MANAGEMENT, LLC | 25.5K +6.1K (+31.7%) | 243.5K +54.6K (+28.9%) | 0.05% +0.011 pp | 0.00% +0.000 pp | USD20.85 -54.2% | 30 qtrs — |
| 91 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 25.2K +6.4K (+34.0%) | 239.9K +56.1K (+30.5%) | 0.05% +0.012 pp | 0.00% +0.000 pp | USD17.32 -44.9% | 7 qtrs — |
| 92 | PURKISS CAPITAL ADVISORS LLC | 25.1K -300.0 (-1.2%) | 239.6K -8.2K (-3.3%) | 0.05% -0.001 pp | 0.11% -0.006 pp | USD12.14 -21.3% | 5 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 66 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.69% | 396.8K | 0.65% |
| 2 | Federated Hermes MDT Small Cap Core ETF FSCC | 0.44% | 723.6K | 0.51% |
| 3 | Global X - S&P Biotech ETF CURE.AX | 0.12% | 44.8K | 0.45% |
| 4 | State Street SPDR S&P Biotech ETF XBI | 0.12% | 13.47M | 0.35% |
| 5 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.04% | 503.8K | 0.40% |
| 6 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.03% | 25.5K | 0.35% |
| 7 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.03% | 380.2K | 0.35% |
| 8 | iShares Ageing Population UCITS ETF AGED.L | 0.03% | 300.4K | 0.40% |
| 9 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.03% | 153.9K | 0.40% |
| 10 | iShares Biotechnology ETF IBB | 0.03% | 3.00M | 0.44% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
100.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+100,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-10 | Kingston Anne Evans | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 10.50 | 1.05M | 100,000 | D | ↗ |
| 2026-03-03 | Zago Wagner M. | Officer | A-Award | A | Stock Option (Right to Buy) | 190,000 | 9.36 | 1.78M | 190,000 | D | ↗ |
| 2026-03-03 | Walker Karin L | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 9.36 | 1.40M | 150,000 | D | ↗ |
| 2026-03-03 | Swanson Chad J. | Officer | A-Award | A | Stock Option (Right to Buy) | 190,000 | 9.36 | 1.78M | 190,000 | D | ↗ |
| 2026-03-03 | Smith Brandon S. | Officer | A-Award | A | Stock Option (Right to Buy) | 190,000 | 9.36 | 1.78M | 190,000 | D | ↗ |
| 2026-03-03 | Nguyen Tran | Officer | A-Award | A | Stock Option (Right to Buy) | 230,000 | 9.36 | 2.15M | 230,000 | D | ↗ |
| 2026-03-03 | Malecek Michael J | Officer | A-Award | A | Stock Option (Right to Buy) | 190,000 | 9.36 | 1.78M | 190,000 | D | ↗ |
| 2026-03-03 | Kinney Gene G. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 520,000 | 9.36 | 4.87M | 520,000 | D | ↗ |
| 2025-07-28 | Zago Wagner M. | Officer | A-Award | A | Ordinary Shares, par value $0.01 per share | 85,000 | 0.00 | — | 85,000 | D | ↗ |
| 2025-07-28 | Walker Karin L | Officer | A-Award | A | Ordinary Shares, par value $0.01 per share | 25,000 | 0.00 | — | 25,000 | D | ↗ |
| 2025-07-28 | Swanson Chad J. | Officer | A-Award | A | Ordinary Shares, par value $0.01 per share | 85,000 | 0.00 | — | 85,000 | D | ↗ |
| 2025-07-28 | Smith Brandon S. | Officer | A-Award | A | Ordinary Shares, par value $0.01 per share | 130,000 | 0.00 | — | 130,000 | D | ↗ |
| 2025-07-28 | Nguyen Tran | Officer | A-Award | A | Ordinary Shares, par value $0.01 per share | 95,000 | 0.00 | — | 97,205 | D | ↗ |
| 2025-07-28 | Malecek Michael J | Officer | A-Award | A | Ordinary Shares, par value $0.01 per share | 80,000 | 0.00 | — | 80,000 | D | ↗ |
| 2025-07-28 | Kinney Gene G. | Director / Officer | A-Award | A | Ordinary Shares, par value $0.01 per share | 140,000 | 0.00 | — | 152,793 | D | ↗ |
| 2025-05-14 | WELCH DANIEL G | Director | A-Award | A | Stock Option (Right to Buy) | 20,183 | 6.89 | 139.0K | 20,183 | D | ↗ |
| 2025-05-14 | Selkoe Dennis J. | Director | A-Award | A | Stock Option (Right to Buy) | 20,183 | 6.89 | 139.0K | 20,183 | D | ↗ |
| 2025-05-14 | Kim Helen Susan | Director | A-Award | A | Stock Option (Right to Buy) | 20,183 | 6.89 | 139.0K | 20,183 | D | ↗ |
| 2025-05-14 | Ekman Lars | Director | A-Award | A | Stock Option (Right to Buy) | 20,183 | 6.89 | 139.0K | 20,183 | D | ↗ |
| 2025-05-14 | Dunn William H. Jr. | Director | A-Award | A | Stock Option (Right to Buy) | 20,183 | 6.89 | 139.0K | 20,183 | D | ↗ |
| 2025-05-14 | Cooke Shane | Director | A-Award | A | Stock Option (Right to Buy) | 20,183 | 6.89 | 139.0K | 20,183 | D | ↗ |
| 2025-05-14 | Cobb Paula K | Director | A-Award | A | Stock Option (Right to Buy) | 20,183 | 6.89 | 139.0K | 20,183 | D | ↗ |
| 2025-05-14 | COLLIER RICHARD T | Director | A-Award | A | Stock Option (Right to Buy) | 20,183 | 6.89 | 139.0K | 20,183 | D | ↗ |
| 2025-05-06 | EcoR1 Capital, LLC | 10% Owner | S-Sale | D | Ordinary Shares | 1,984,053 | 7.64 | 15.16M | 5,304,596 | I | ↗ |
| 2025-05-05 | EcoR1 Capital, LLC | 10% Owner | S-Sale | D | Ordinary Shares | 977,693 | 8.11 | 7.93M | 7,288,649 | I | ↗ |
| 2025-05-02 | EcoR1 Capital, LLC | 10% Owner | S-Sale | D | Ordinary Shares | 3,317,938 | 8.36 | 27.74M | 8,266,342 | I | ↗ |
| 2025-03-05 | Zago Wagner M. | Officer | A-Award | A | Stock Option (Right to Buy) | 107,500 | 14.95 | 1.61M | 107,500 | D | ↗ |
| 2025-03-05 | Walker Karin L | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 14.95 | 1.05M | 70,000 | D | ↗ |
| 2025-03-05 | Swanson Chad J. | Officer | A-Award | A | Stock Option (Right to Buy) | 107,500 | 14.95 | 1.61M | 107,500 | D | ↗ |
| 2025-03-05 | Smith Brandon S. | Officer | A-Award | A | Stock Option (Right to Buy) | 107,500 | 14.95 | 1.61M | 107,500 | D | ↗ |
| 2025-03-05 | Nguyen Tran | Officer | A-Award | A | Stock Option (Right to Buy) | 107,500 | 14.95 | 1.61M | 107,500 | D | ↗ |
| 2025-03-05 | Malecek Michael J | Officer | A-Award | A | Stock Option (Right to Buy) | 107,500 | 14.95 | 1.61M | 107,500 | D | ↗ |
| 2025-03-05 | Kinney Gene G. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 375,000 | 14.95 | 5.61M | 375,000 | D | ↗ |
| 2025-03-05 | Karp Carol D. | Officer | A-Award | A | Stock Option (Right to Buy) | 107,500 | 14.95 | 1.61M | 107,500 | D | ↗ |
| 2025-03-05 | Ford David A | Officer | A-Award | A | Stock Option (Right to Buy) | 107,500 | 14.95 | 1.61M | 107,500 | D | ↗ |
| 2025-01-15 | SCULLY WILLIAM P | 10% Owner | G-Gift | D | Ordinary Shares, par value $0.01 per share | 12,000 | 0.00 | — | 47,000 | I | ↗ |
| 2025-01-14 | SCULLY WILLIAM P | 10% Owner | P-Purchase | A | Ordinary Shares, par value $0.01 per share | 100,000 | 12.79 | 1.28M | 735,993 | D | ↗ |
| 2025-01-03 | SCULLY WILLIAM P | 10% Owner | G-Gift | D | Ordinary Shares, par value $0.01 per share | 1,000 | 0.00 | — | 635,993 | D | ↗ |
| 2025-01-02 | SCULLY WILLIAM P | 10% Owner | G-Gift | D | Ordinary Shares, par value $0.01 per share | 13,200 | 0.00 | — | 636,993 | D | ↗ |
| 2024-12-31 | SCULLY WILLIAM P | 10% Owner | P-Purchase | A | Ordinary Shares, par value $0.01 per share | 1,200 | 13.37 | 16.0K | 619,393 | D | ↗ |
| 2024-12-20 | SCULLY WILLIAM P | 10% Owner | G-Gift | D | Ordinary Shares, par value $0.01 per share | 40,000 | 0.00 | — | 59,000 | I | ↗ |
| 2024-12-19 | SCULLY WILLIAM P | 10% Owner | G-Gift | D | Ordinary Shares, par value $0.01 per share | 681,000 | 0.00 | — | 616,693 | D | ↗ |
| 2024-12-18 | SCULLY WILLIAM P | 10% Owner | P-Purchase | A | Ordinary Shares, par value $0.01 per share | 73,436 | 13.93 | 1.02M | 1,297,693 | D | ↗ |
| 2024-12-17 | SCULLY WILLIAM P | 10% Owner | — | — | Ordinary Shares, par value $0.01 per share | 0 | 0.00 | — | 794,257 | D | ↗ |
| 2024-10-01 | Swanson Chad J. | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 16.65 | 666.0K | 40,000 | D | ↗ |
| 2024-09-27 | Swanson Chad J. | Officer | — | — | Stock Option (Right to Buy) | 85,000 | 53.67 | 4.56M | 0 | D | ↗ |
| 2024-05-15 | WELCH DANIEL G | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 22.39 | 335.9K | 15,000 | — | ↗ |
| 2024-05-15 | Selkoe Dennis J. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 22.39 | 335.9K | 15,000 | — | ↗ |
| 2024-05-15 | Kim Helen Susan | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 22.39 | 335.9K | 15,000 | — | ↗ |
| 2024-05-15 | Ekman Lars | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 22.39 | 335.9K | 15,000 | — | ↗ |
| 2024-05-15 | Dunn William H. Jr. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 22.39 | 335.9K | 15,000 | — | ↗ |
| 2024-05-15 | Cooke Shane | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 22.39 | 335.9K | 15,000 | — | ↗ |
| 2024-05-15 | Cobb Paula K | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 22.39 | 335.9K | 15,000 | — | ↗ |
| 2024-05-15 | COLLIER RICHARD T | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 22.39 | 335.9K | 15,000 | — | ↗ |
| 2024-03-01 | Ford David A | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 28.53 | 2.43M | 85,000 | — | ↗ |
| 2024-02-27 | Zago Wagner M. | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 30.30 | 2.58M | 85,000 | — | ↗ |
| 2024-02-27 | Walker Karin L | Officer | A-Award | A | Stock Option (Right to Buy) | 54,000 | 30.30 | 1.64M | 54,000 | — | ↗ |
| 2024-02-27 | Smith Brandon S. | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 30.30 | 2.58M | 85,000 | — | ↗ |
| 2024-02-27 | Nguyen Tran | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 30.30 | 2.58M | 85,000 | — | ↗ |
| 2024-02-27 | Malecek Michael J | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 30.30 | 2.58M | 85,000 | — | ↗ |
| 2024-02-27 | Kinney Gene G. | Officer | A-Award | A | Stock Option (Right to Buy) | 307,000 | 30.30 | 9.30M | 307,000 | — | ↗ |
| 2024-02-27 | Karp Carol D. | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 30.30 | 2.58M | 85,000 | — | ↗ |
| 2024-02-27 | Garren Hideki | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 30.30 | 2.58M | 85,000 | — | ↗ |
| 2024-02-21 | WELCH DANIEL G | Director | A-Award | A | Stock Option (Right to Buy) | 132,000 | 27.05 | 3.57M | 132,000 | — | ↗ |
| 2024-01-24 | Walker Karin L | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 13.53 | 67.7K | 15,000 | — | ↗ |
| 2023-12-20 | Walker Karin L | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 1,678 | 36.68 | 61.5K | 3,322 | — | ↗ |
| 2023-11-30 | Walker Karin L | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 13.53 | 67.7K | 25,000 | — | ↗ |
| 2023-10-25 | Walker Karin L | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 1,789 | 40.27 | 72.0K | 3,211 | — | ↗ |
| 2023-10-11 | Smith Brandon S. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,000 | 11.12 | 44.5K | 218,667 | — | ↗ |
| 2023-10-04 | Karp Carol D. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 12.15 | 60.8K | 45,000 | — | ↗ |
| 2023-09-27 | Malecek Michael J | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 10.27 | 51.4K | 90,000 | — | ↗ |
| 2023-09-19 | Walker Karin L | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 5,000 | 52.36 | 261.8K | 0 | — | ↗ |
| 2023-09-13 | Smith Brandon S. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,000 | 11.12 | 44.5K | 222,667 | — | ↗ |
| 2023-09-13 | Garren Hideki | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,000 | 24.90 | 49.8K | 192,000 | — | ↗ |
| 2023-09-06 | Karp Carol D. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 12.15 | 60.8K | 50,000 | — | ↗ |
| 2023-08-30 | Malecek Michael J | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 2,322 | 54.58 | 126.7K | 2,678 | — | ↗ |
| 2023-08-18 | Walker Karin L | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 15.04 | 75.2K | 5,481 | — | ↗ |
| 2023-08-16 | Smith Brandon S. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,000 | 11.12 | 44.5K | 226,667 | — | ↗ |
| 2023-08-16 | Garren Hideki | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 748 | 58.93 | 44.1K | 374 | — | ↗ |
| 2023-08-02 | Zago Wagner M. | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 229 | 68.07 | 15.6K | 0 | — | ↗ |
| 2023-08-02 | Karp Carol D. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 12.15 | 60.8K | 55,000 | — | ↗ |
| 2023-07-26 | Malecek Michael J | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 10.27 | 51.4K | 100,000 | — | ↗ |
| 2023-07-19 | Walker Karin L | Officer | M-Exempt | D | Stock Option (right to buy) | 5,000 | 15.04 | 75.2K | 10,481 | — | ↗ |
| 2023-07-12 | Smith Brandon S. | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 800 | 67.95 | 54.4K | 0 | — | ↗ |
| 2023-07-12 | Garren Hideki | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 92 | 68.20 | 6.3K | 0 | — | ↗ |
| 2023-07-05 | Zago Wagner M. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,000 | 12.15 | 48.6K | 62,000 | — | ↗ |
| 2023-07-05 | Karp Carol D. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 12.15 | 60.8K | 60,000 | — | ↗ |
| 2023-07-03 | Selkoe Dennis J. | Director | S-Sale | D | Ordinary Shares, par value $0.01 per share | 5,000 | 67.43 | 337.2K | 2,845 | — | ↗ |
| 2023-06-28 | Malecek Michael J | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 1,240 | 69.07 | 85.6K | 3,760 | — | ↗ |
| 2023-06-20 | Walker Karin L | Officer | M-Exempt | D | Stock Option (right to buy) | 5,000 | 15.04 | 75.2K | 15,481 | — | ↗ |
| 2023-06-16 | Garren Hideki | Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,331 | 24.90 | 182.5K | 198,000 | — | ↗ |
| 2023-06-14 | Smith Brandon S. | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 1,098 | 72.52 | 79.6K | 4,235 | — | ↗ |
| 2023-06-14 | Garren Hideki | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,669 | 24.90 | 116.3K | 205,331 | — | ↗ |
| 2023-06-07 | Zago Wagner M. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 15,000 | 29.81 | 447.2K | 0 | — | ↗ |
| 2023-06-07 | Karp Carol D. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 15,000 | 13.53 | 203.0K | 35,000 | — | ↗ |
| 2023-05-31 | Malecek Michael J | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 10.27 | 51.4K | 110,000 | — | ↗ |
| 2023-05-19 | Walker Karin L | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 2,823 | 73.63 | 207.9K | 2,177 | — | ↗ |
| 2023-05-17 | Selkoe Dennis J. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 76.00 | 1.14M | 15,000 | — | ↗ |
| 2023-05-17 | Nguyen Tran | Officer | M-Exempt | D | Stock Option (Right to Buy) | 45,000 | 29.81 | 1.34M | 0 | — | ↗ |
| 2023-05-17 | Kinney Gene G. | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 19,864 | 73.60 | 1.46M | 27,727 | — | ↗ |
| 2023-05-17 | Kim Helen Susan | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 76.00 | 1.14M | 15,000 | — | ↗ |
| 2023-05-17 | Harfstrand Karl Anders Olof | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 76.00 | 1.14M | 15,000 | — | ↗ |
| 2023-05-17 | Ekman Lars | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 76.00 | 1.14M | 15,000 | — | ↗ |
| 2023-05-17 | Dunn William H. Jr. | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 76.00 | 2.28M | 30,000 | — | ↗ |
| 2023-05-17 | Cooke Shane | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 76.00 | 1.14M | 15,000 | — | ↗ |
| 2023-05-17 | Cobb Paula K | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 76.00 | 1.14M | 15,000 | — | ↗ |
| 2023-05-17 | COLLIER RICHARD T | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 76.00 | 1.14M | 15,000 | — | ↗ |
| 2023-05-16 | Dunn William H. Jr. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-05-03 | Selkoe Dennis J. | Director | M-Exempt | A | Ordinary Shares, par value $0.01 per share | 9,000 | 23.97 | 215.7K | 17,845 | — | ↗ |
| 2023-04-26 | Malecek Michael J | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 320 | 54.25 | 17.4K | 0 | — | ↗ |
| 2023-04-19 | Walker Karin L | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 2,083 | 53.25 | 110.9K | 0 | — | ↗ |
| 2023-03-29 | Malecek Michael J | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 10.27 | 51.4K | 120,000 | — | ↗ |
| 2023-03-15 | Walker Karin L | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 10,569 | 48.66 | 514.3K | 0 | — | ↗ |
| 2023-03-15 | Nguyen Tran | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 6.73 | 67.3K | 0 | — | ↗ |
| 2023-03-15 | Malecek Michael J | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 8,564 | 48.67 | 416.8K | 0 | — | ↗ |
| 2023-03-15 | Garren Hideki | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 6,000 | 48.16 | 289.0K | 6,000 | — | ↗ |
| 2023-03-02 | Zago Wagner M. | Officer | A-Award | A | Stock Option (Right to Buy) | 48,000 | 52.97 | 2.54M | 48,000 | — | ↗ |
| 2023-03-02 | Walker Karin L | Officer | A-Award | A | Stock Option (Right to Buy) | 38,000 | 52.97 | 2.01M | 38,000 | — | ↗ |
| 2023-03-02 | Smith Brandon S. | Officer | A-Award | A | Stock Option (Right to Buy) | 48,000 | 52.97 | 2.54M | 48,000 | — | ↗ |
| 2023-03-02 | Nguyen Tran | Officer | A-Award | A | Stock Option (Right to Buy) | 48,000 | 52.97 | 2.54M | 48,000 | — | ↗ |
| 2023-03-02 | Malecek Michael J | Officer | A-Award | A | Stock Option (Right to Buy) | 48,000 | 52.97 | 2.54M | 48,000 | — | ↗ |
| 2023-03-02 | Kinney Gene G. | Officer | A-Award | A | Stock Option (Right to Buy) | 155,000 | 52.97 | 8.21M | 155,000 | — | ↗ |
| 2023-03-02 | Karp Carol D. | Officer | A-Award | A | Stock Option (Right to Buy) | 48,000 | 52.97 | 2.54M | 48,000 | — | ↗ |
| 2023-03-02 | Garren Hideki | Officer | A-Award | A | Stock Option (Right to Buy) | 48,000 | 52.97 | 2.54M | 48,000 | — | ↗ |
| 2023-02-15 | Nguyen Tran | Officer | M-Exempt | A | Ordinary Shares, par value $0.01 per share | 10,000 | 6.73 | 67.3K | 13,200 | — | ↗ |
| 2023-01-18 | Nguyen Tran | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 2,085 | 56.32 | 117.4K | 3,838 | — | ↗ |
| 2023-01-10 | Cooke Shane | Director | M-Exempt | A | Ordinary Shares, par value $0.01 per share | 5,000 | 6.41 | 32.1K | 5,000 | — | ↗ |
| 2023-01-05 | COLLIER RICHARD T | Director | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 0.00 | — | 0 | — | ↗ |
| 2023-01-03 | Ekman Lars | Director | S-Sale | D | Ordinary Shares, par value $0.01 per share | 10 | 59.46 | 594.60 | 312 | — | ↗ |
| 2022-12-21 | Nguyen Tran | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-12-12 | Cooke Shane | Director | S-Sale | D | Ordinary Shares, par value $0.01 per share | 332 | 58.93 | 19.6K | 4,668 | — | ↗ |
| 2022-12-05 | COLLIER RICHARD T | Director | M-Exempt | A | Ordinary Shares, par value $0.01 per share | 5,000 | 6.41 | 32.1K | 6,219 | — | ↗ |
| 2022-12-01 | Garren Hideki | Director / Officer | M-Exempt | A | Ordinary Shares, par value $0.01 per share | 4,000 | 24.90 | 99.6K | 4,000 | — | ↗ |
| 2022-12-01 | Ekman Lars | Director | S-Sale | D | Ordinary Shares, par value $0.01 per share | 6,021 | 62.12 | 374.0K | 243 | — | ↗ |
| 2022-11-30 | Malecek Michael J | Director / Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 494 | 64.13 | 31.7K | 587 | — | ↗ |
| 2022-11-23 | Nguyen Tran | Director / Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 4,547 | 60.53 | 275.2K | 8,653 | — | ↗ |
| 2022-11-18 | Walker Karin L | Officer | M-Exempt | D | Stock Option (right to buy) | 10,000 | 0.00 | — | 55,481 | — | ↗ |
| 2022-11-10 | Cooke Shane | Director | S-Sale | D | Ordinary Shares, par value $0.01 per share | 255 | 54.20 | 13.8K | 4,745 | — | ↗ |
| 2022-11-07 | COLLIER RICHARD T | Director | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-11-01 | Garren Hideki | Director / Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 511 | 62.41 | 31.9K | 0 | — | ↗ |
| 2022-11-01 | Ekman Lars | Director | S-Sale | D | Ordinary Shares, par value $0.01 per share | 3,312 | 64.26 | 212.8K | 1,904 | — | ↗ |
| 2022-10-27 | Malecek Michael J | Officer | M-Exempt | D | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 145,000 | — | ↗ |
| 2022-10-26 | Malecek Michael J | Officer | M-Exempt | A | Ordinary Shares, par value $0.01 per share | 65,000 | 10.27 | 667.6K | 65,000 | — | ↗ |
| 2022-10-24 | Walker Karin L | Officer | M-Exempt | D | Stock Option (right to buy) | 20,000 | 0.00 | — | 65,481 | — | ↗ |
| 2022-10-19 | Nguyen Tran | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 171 | 58.17 | 9.9K | 3,200 | — | ↗ |
| 2022-10-10 | Cooke Shane | Director | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-10-05 | COLLIER RICHARD T | Director | S-Sale | D | Ordinary Shares, par value $0.01 per share | 3,404 | 57.97 | 197.3K | 1,925 | — | ↗ |
| 2022-10-03 | Garren Hideki | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 4,000 | 60.90 | 243.6K | 0 | — | ↗ |
| 2022-10-03 | Ekman Lars | Director | S-Sale | D | Ordinary Shares, par value $0.01 per share | 3,508 | 60.32 | 211.6K | 12,568 | — | ↗ |
| 2022-09-28 | Kinney Gene G. | Director | S-Sale | D | Ordinary Shares, par value $0.01 per share | 1,342 | 55.32 | 74.2K | 13,205 | — | ↗ |
| 2022-09-28 | Ekman Lars | Director | M-Exempt | D | Stock Option (right to buy) | 31,666 | 0.00 | — | 63,334 | — | ↗ |
| 2022-09-28 | Cooke Shane | Director | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-09-28 | COLLIER RICHARD T | Director | M-Exempt | A | Ordinary Shares, par value $0.01 per share | 25,000 | 6.41 | 160.3K | 26,219 | — | ↗ |
| 2022-09-21 | Kinney Gene G. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,720 | 6.41 | 17.4K | 16,412 | — | ↗ |
| 2022-08-31 | Kim Helen Susan | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-08-30 | Kim Helen Susan | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-08-24 | Nguyen Tran | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 0.00 | — | 70,000 | — | ↗ |
| 2022-08-17 | Kinney Gene G. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,181 | 6.41 | 14.0K | 19,132 | — | ↗ |
| 2022-08-12 | Kinney Gene G. | Officer | M-Exempt | A | Ordinary Shares, par value $0.01 per share | 20,284 | 6.41 | 130.0K | 33,077 | — | ↗ |
| 2022-08-11 | Kinney Gene G. | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 13,650 | 32.16 | 438.9K | 12,793 | — | ↗ |
| 2022-08-10 | Kinney Gene G. | Director | M-Exempt | A | Ordinary Shares, par value $0.01 per share | 991 | 6.41 | 6.4K | 13,784 | — | ↗ |
| 2022-08-05 | Kinney Gene G. | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 16,833 | 32.77 | 551.6K | 17,466 | — | ↗ |
| 2022-08-04 | Kinney Gene G. | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 20,954 | 32.18 | 674.3K | 12,793 | — | ↗ |
| 2022-08-01 | Garren Hideki | Officer | M-Exempt | A | Ordinary Shares, par value $0.01 per share | 4,000 | 24.90 | 99.6K | 4,000 | — | ↗ |
| 2022-07-27 | Kinney Gene G. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 376 | 6.41 | 2.4K | 98,698 | — | ↗ |
| 2022-07-20 | Nguyen Tran | Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,320 | 0.00 | — | 80,000 | — | ↗ |
| 2022-07-20 | Cooke Shane | Director | M-Exempt | D | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-07-06 | Garren Hideki | Officer | M-Exempt | A | Ordinary Shares, par value $0.01 per share | 8,000 | 24.90 | 199.2K | 8,000 | — | ↗ |
| 2022-05-18 | Selkoe Dennis J. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-05-18 | Patel Sanjiv | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-05-18 | Harfstrand Karl Anders Olof | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-05-18 | Ekman Lars | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 25.60 | 384.0K | 15,000 | — | ↗ |
| 2022-05-18 | Cooke Shane | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-05-18 | Cobb Paula K | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-05-18 | COLLIER RICHARD T | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-05-05 | EcoR1 Capital, LLC | Director | S-Sale | D | Ordinary Shares | 1,062,736 | 29.02 | 30.84M | 11,584,280 | — | ↗ |
| 2022-04-11 | Cooke Shane | Director | S-Sale | D | Ordinary Shares, par value $0.01 per share | 3,002 | 34.48 | 103.5K | 1,998 | — | ↗ |
| 2022-04-05 | COLLIER RICHARD T | Director | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 6.41 | 32.1K | 45,000 | — | ↗ |
| 2022-02-23 | Zago Wagner M. | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 32.45 | 2.76M | 85,000 | — | ↗ |
| 2022-02-23 | Walker Karin L | Officer | A-Award | A | Stock Option (Right to Buy) | 45,500 | 32.45 | 1.48M | 45,500 | — | ↗ |
| 2022-02-23 | Tripuraneni Radhika | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 32.45 | 1.62M | 50,000 | — | ↗ |
| 2022-02-23 | Smith Brandon S. | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 32.45 | 2.76M | 85,000 | — | ↗ |
| 2022-02-23 | Nguyen Tran | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 32.45 | 2.76M | 85,000 | — | ↗ |
| 2022-02-23 | Malecek Michael J | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 32.45 | 2.76M | 85,000 | — | ↗ |
| 2022-02-23 | Kinney Gene G. | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 32.45 | 8.11M | 250,000 | — | ↗ |
| 2022-02-23 | Karp Carol D. | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 32.45 | 2.76M | 85,000 | — | ↗ |
| 2022-02-23 | Garren Hideki | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 32.45 | 2.76M | 85,000 | — | ↗ |
| 2022-01-12 | EcoR1 Capital, LLC | 10% Owner | P-Purchase | A | Ordinary Shares | 300,000 | 37.50 | 11.25M | 11,584,280 | — | ↗ |
| 2022-01-03 | Selkoe Dennis J. | Director | M-Exempt | A | Ordinary Shares, par value $0.01 per share | 5,000 | 9.23 | 46.2K | 7,845 | — | ↗ |
| 2021-11-23 | Walker Karin L | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 1,819 | 58.43 | 106.3K | 0 | — | ↗ |
| 2021-11-19 | Malecek Michael J | Officer | M-Exempt | A | Ordinary Shares, par value $0.01 per share | 10,000 | 10.27 | 102.7K | 10,000 | — | ↗ |
| 2021-11-01 | Karp Carol D. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 15.04 | 150.4K | 120,000 | — | ↗ |
| 2021-10-27 | Malecek Michael J | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 10.27 | 102.7K | 240,000 | — | ↗ |
| 2021-10-20 | Walker Karin L | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 2,185 | 61.94 | 135.3K | 0 | — | ↗ |
| 2021-10-01 | Selkoe Dennis J. | Director | S-Sale | D | Ordinary Shares, par value $0.01 per share | 706 | 69.69 | 49.2K | 2,845 | — | ↗ |
| 2021-10-01 | Karp Carol D. | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 213 | 70.44 | 15.0K | 0 | — | ↗ |
| 2021-09-29 | Smith Brandon S. | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 70.81 | 1.77M | 25,000 | — | ↗ |
| 2021-09-09 | Karp Carol D. | Officer | S-Sale | D | Ordinary Shares, par value $0.01 per share | 4,542 | 72.63 | 329.9K | 0 | — | ↗ |
| 2021-07-30 | Selkoe Dennis J. | Director | M-Exempt | D | Stock Option (Right to Buy) | 1,500 | 9.23 | 13.8K | 16,000 | — | ↗ |
| 2021-07-14 | HENNEY CHRISTOPHER S | Director | S-Sale | D | Ordinary Shares, par value $0.01 per share | 9,108 | 55.31 | 503.8K | 2,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-30.0K
Shares Outstanding
53.83M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Gene G. Kinney, Ph.D. President and Chief Executive Officer | 693.0K | — | 961.8K | 3.81M | 415.8K | 15.8K | 5.90M | 80.93% | ↗ |
| 2 | 2025 | Brandon S. Smith Chief Operating Officer | 540.7K | — | 893.1K | 1.09M | 270.4K | 15.8K | 2.81M | 70.60% | ↗ |
| 3 | 2025 | Tran B. Nguyen Chief Strategy Officer and Chief Financial Officer | 600.4K | — | 652.7K | 1.09M | 300.2K | 15.8K | 2.66M | 65.57% | ↗ |
| 4 | 2025 | Chad J. Swanson, Ph.D Chief Dev. Officer | 516.7K | — | 584.0K | 1.09M | 206.7K | 15.8K | 2.42M | 69.40% | ↗ |
| 5 | 2025 | Wagner M. Zago, Ph.D. Chief Scientific Officer | 514.2K | — | 584.0K | 1.09M | 205.7K | 15.8K | 2.41M | 69.50% | ↗ |
| 6 | 2024 | Gene G. Kinney, Ph.D. President and Chief Executive Officer | 654.1K | — | — | 6.17M | 392.5K | 15.5K | 7.23M | 85.31% | ↗ |
| 7 | 2024 | Tran B. Nguyen Chief Strategy Officer and Chief Financial Officer | 580.1K | — | — | 1.71M | 290.0K | 15.5K | 2.59M | 65.85% | ↗ |
| 8 | 2024 | Brandon S. Smith Chief Operating Officer | 520.3K | — | — | 1.71M | 260.2K | 15.5K | 2.50M | 68.21% | ↗ |
| 9 | 2024 | Carol D. Karp Chief Regulatory Officer | 514.3K | — | — | 1.71M | 205.7K | 15.5K | 2.44M | 69.90% | ↗ |
| 10 | 2024 | Wagner M. Zago, Ph.D. Chief Scientific Officer | 492.0K | — | — | 1.71M | 196.8K | 15.5K | 2.41M | 70.80% | ↗ |
| 11 | 2023 | Gene G. Kinney, Ph.D. President and Chief Executive Officer | 630.5K | — | — | 6.04M | 359.4K | 14.9K | 7.04M | 85.73% | ↗ |
| 12 | 2023 | Tran B. Nguyen Chief Strategy Officer and Chief Financial Officer | 550.4K | — | — | 1.87M | 264.9K | 14.9K | 2.70M | 69.26% | ↗ |
| 13 | 2023 | Hideki Garren, M.D., Ph.D. Chief Medical Officer | 535.9K | — | — | 1.87M | 257.9K | 14.9K | 2.68M | 69.81% | ↗ |
| 14 | 2023 | Brandon S. Smith Chief Operating Officer | 501.6K | — | — | 1.87M | 241.4K | 14.9K | 2.63M | 71.16% | ↗ |
| 15 | 2023 | Carol D. Karp Chief Regulatory Officer | 495.8K | — | — | 1.87M | 190.9K | 14.9K | 2.57M | 72.72% | ↗ |
| 16 | 2022 | Gene G. Kinney, Ph.D. President and Chief Executive Officer | 600.5K | — | — | 5.71M | 414.4K | 15.3K | 6.74M | 84.71% | ↗ |
| 17 | 2022 | Hideki Garren, M.D., Ph.D. Chief Medical Officer | 510.4K | — | — | 1.94M | 283.9K | 15.3K | 2.75M | 70.56% | ↗ |
| 18 | 2022 | Tran B. Nguyen Chief Strategy Officer and Chief Financial Officer | 480.4K | — | — | 1.94M | 267.2K | 15.3K | 2.70M | 71.78% | ↗ |
| 19 | 2022 | Brandon S. Smith Chief Operating Officer | 476.3K | — | — | 1.94M | 264.9K | 15.3K | 2.70M | 71.95% | ↗ |
| 20 | 2022 | Carol D. Karp Chief Regulatory Officer | 472.2K | — | — | 1.94M | 210.1K | 15.3K | 2.64M | 73.55% | ↗ |
| 21 | 2021 | Hideki Garren, M.D., Ph.D. Chief Medical Officer | 364.0K | 50.0K | — | 4.32M | 290.9K | 14.5K | 5.04M | 85.72% | ↗ |
| 22 | 2021 | Gene G. Kinney, Ph.D. President and Chief Executive Officer | 573.3K | — | — | 3.90M | 429.9K | 14.5K | 4.92M | 79.31% | ↗ |
| 23 | 2021 | Brandon S. Smith Chief Operating Officer | 420.7K | — | — | 2.11M | 213.2K | 14.5K | 2.76M | 76.53% | ↗ |
| 24 | 2021 | Tran B. Nguyen Chief Strategy Officer and Chief Financial Officer | 458.6K | — | — | 1.31M | 272.3K | 14.5K | 2.06M | 63.75% | ↗ |
| 25 | 2021 | Carol D. Karp Chief Regulatory Officer | 450.7K | — | — | 873.8K | 214.1K | 14.5K | 1.55M | 56.26% | ↗ |
| 26 | 2020 | Gene G. Kinney, Ph.D. President and Chief Executive Officer | 554.3K | — | — | 2.53M | 332.6K | 14.3K | 3.43M | 73.71% | ↗ |
| 27 | 2020 | Brandon S. Smith Chief Operating Officer | 333.3K | 100.0K | — | 1.84M | 133.3K | 14.3K | 2.42M | 76.04% | ↗ |
| 28 | 2020 | Brandon S. Smith Chief Business Officer | 333.3K | 100.0K | — | 1.84M | 133.3K | 14.3K | 2.42M | 76.04% | ↗ |
| 29 | 2020 | Tran B. Nguyen Chief Operating Officer and Chief Financial Officer | 443.4K | — | — | 884.3K | 221.7K | 14.3K | 1.56M | 56.55% | ↗ |
| 30 | 2020 | Tran B. Nguyen Chief Strategy Officer and Chief Financial Officer | 443.4K | — | — | 884.3K | 221.7K | 14.3K | 1.56M | 56.55% | ↗ |
| 31 | 2020 | Carol D. Karp Chief Regulatory Officer | 435.8K | — | — | 589.5K | 174.3K | 14.3K | 1.21M | 48.56% | ↗ |
| 32 | 2020 | Michael J. Malecek Chief Legal Officer and Company Secretary | 410.0K | — | — | 589.5K | 164.0K | 14.3K | 1.18M | 50.05% | ↗ |
| 33 | 2019 | Gene G. Kinney, Ph.D. President and Chief Executive Officer | 538.1K | — | — | 2.34M | 322.9K | 14.0K | 3.21M | 72.77% | ↗ |
| 34 | 2019 | Michael J. Malecek Chief Legal Officer and Company Secretary | 207.7K | 125.0K | — | 1.79M | 160.0K | 8.4K | 2.29M | 78.11% | ↗ |
| 35 | 2019 | Tran B. Nguyen Chief Operating Officer and Chief Financial Officer | 430.5K | — | — | 906.7K | 215.3K | 14.0K | 1.57M | 57.88% | ↗ |
| 36 | 2019 | Tran B. Nguyen Chief Strategy Officer and Chief Financial Officer | 430.5K | — | — | 906.7K | 215.3K | 14.0K | 1.57M | 57.88% | ↗ |
| 37 | 2019 | Carol D. Karp Chief Regulatory Officer | 423.1K | — | — | 477.2K | 169.2K | 14.0K | 1.08M | 44.04% | ↗ |
| 38 | 2019 | Radhika Tripuraneni, M.D., M.P.H. Chief Development Officer | 403.2K | — | — | 477.2K | 161.3K | 14.0K | 1.06M | 45.20% | ↗ |
| 39 | 2018 | Gene G. Kinney, Ph.D. President and Chief Executive Officer | 525.0K | — | — | 10.58M | 283.5K | 12.4K | 11.40M | 92.80% | ↗ |
| 40 | 2018 | Tran B. Nguyen Chief Operating Officer and Chief Financial Officer | 412.5K | — | — | 4.36M | 173.1K | 12.4K | 4.96M | 87.94% | ↗ |
| 41 | 2018 | Carol D. Karp Chief Regulatory Officer | 410.7K | — | — | 2.86M | 151.9K | 12.4K | 3.44M | 83.27% | ↗ |
| 42 | 2018 | A. W. Homan Chief Legal Officer and Company Secretary | 366.4K | — | — | 2.86M | 135.6K | 12.4K | 3.38M | 84.77% | ↗ |
| 43 | 2018 | Wagner M. Zago, Ph.D. Chief Scientific Officer | 340.4K | — | — | 2.86M | 126.0K | 12.4K | 3.34M | 85.67% | ↗ |
| 44 | 2017 | Gene G. Kinney, Ph.D. President and Chief Executive Officer | 520.8K | — | — | 4.30M | 312.5K | 13.5K | 5.15M | 83.55% | ↗ |
| 45 | 2017 | Sarah B. Noonberg, M.D., Ph.D. Former Chief Medical Officer | 310.0K | 100.0K | — | 3.64M | 124.0K | 8.1K | 4.18M | 87.04% | ↗ |
| 46 | 2017 | Tran B. Nguyen Chief Financial Officer | 399.2K | — | — | 2.69M | 159.7K | 13.5K | 3.26M | 82.45% | ↗ |
| 47 | 2017 | Tran B. Nguyen Chief Operating Officer and Chief Financial Officer | 399.2K | — | — | 2.69M | 159.7K | 13.5K | 3.26M | 82.45% | ↗ |
| 48 | 2017 | A. W. Homan Chief Legal Officer and Company Secretary | 353.3K | — | — | 1.97M | 141.3K | 13.5K | 2.48M | 79.51% | ↗ |
| 49 | 2017 | A. W. Homan Chief Legal Officer | 353.3K | — | — | 1.97M | 141.3K | 13.5K | 2.48M | 79.51% | ↗ |
| 50 | 2017 | Tara Nickerson, Ph.D. Chief Business Officer | 339.6K | — | — | 1.61M | 135.8K | 13.5K | 2.10M | 76.74% | ↗ |
| 51 | 2017 | Wagner M. Zago, Ph.D. Chief Scientific Officer | 310.2K | — | — | 1.38M | 113.2K | 13.5K | 1.82M | 75.94% | ↗ |
| 52 | 2017 | Carol D. Karp Chief Regulatory Officer | 400.0K | — | — | — | 160.0K | 13.5K | 573.5K | 0.00% | ↗ |
| 53 | 2016 | Dale B. Schenk, Ph.D. Former President and Chief Executive Officer | 401.7K | — | — | 4.53M | 253.1K | 1.25M | 6.43M | 70.45% | ↗ |
| 54 | 2016 | Gene G. Kinney, Ph.D. President and Chief Executive Officer | 425.0K | — | — | 4.09M | 208.7K | 11.9K | 4.74M | 86.37% | ↗ |
| 55 | 2016 | Carol D. Karp Chief Regulatory Officer | 19.7K | — | — | 3.56M | — | 304.7K | 3.88M | 91.64% | ↗ |
| 56 | 2016 | Tran B. Nguyen Chief Operating Officer and Chief Financial Officer | 366.7K | — | — | 1.47M | 154.0K | 11.9K | 2.01M | 73.45% | ↗ |
| 57 | 2016 | Tran B. Nguyen Chief Financial Officer | 366.7K | — | — | 1.47M | 154.0K | 11.9K | 2.01M | 73.45% | ↗ |
| 58 | 2016 | Martin Koller, M.D. Chief Medical Officer | 369.5K | — | — | 1.13M | 153.3K | 11.9K | 1.67M | 67.94% | ↗ |
| 59 | 2016 | A. W. Homan Chief Legal Officer | 338.3K | — | — | 1.02M | 142.1K | 11.9K | 1.51M | 67.45% | ↗ |
| 60 | 2016 | A. W. Homan Chief Legal Officer and Company Secretary | 338.3K | — | — | 1.02M | 142.1K | 11.9K | 1.51M | 67.45% | ↗ |
| 61 | 2016 | Tara Nickerson, Ph.D. Chief Business Officer | 317.8K | — | — | 793.3K | 131.9K | 11.9K | 1.25M | 63.22% | ↗ |
| 62 | 2016 | Wagner M. Zago, Ph.D. Chief Scientific Officer | 246.8K | — | — | 476.0K | 75.9K | 11.9K | 810.6K | 58.72% | ↗ |
| 63 | 2015 | Dale B. Schenk, Ph.D. Former President and Chief Executive Officer | 515.8K | — | — | 2.78M | 263.1K | 11.3K | 3.57M | 77.90% | ↗ |
| 64 | 2015 | Dale B. Schenk, Ph.D. President and Chief Executive Officer | 515.8K | — | — | 2.78M | 263.1K | 11.3K | 3.57M | 77.90% | ↗ |
| 65 | 2015 | Gene G. Kinney, Ph.D. Chief Scientific Officer and Head of Research and Development | 369.8K | — | — | 1.21M | 131.3K | 11.3K | 1.72M | 70.20% | ↗ |
| 66 | 2015 | Gene G. Kinney, Ph.D. President and Chief Executive Officer | 369.8K | — | — | 1.21M | 131.3K | 11.3K | 1.72M | 70.20% | ↗ |
| 67 | 2015 | Tran B. Nguyen Chief Financial Officer | 348.1K | — | — | 1.02M | 128.8K | 11.3K | 1.51M | 67.66% | ↗ |
| 68 | 2015 | Martin Koller, M.D. Chief Medical Officer | 358.3K | — | — | 928.3K | 123.6K | 11.3K | 1.42M | 65.30% | ↗ |
| 69 | 2015 | A. W. Homan Chief Legal Officer | 329.0K | — | — | 789.0K | 116.8K | 11.3K | 1.25M | 63.32% | ↗ |
| 70 | 2015 | Tara Nickerson, Ph.D. Chief Business Officer | 307.9K | — | — | 696.2K | 106.2K | 11.3K | 1.12M | 62.07% | ↗ |
| 71 | 2014 | Dale B. Schenk, Ph.D. President and Chief Executive Officer | 491.7K | — | — | 2.23M | 295.0K | 11.7K | 3.03M | 73.61% | ↗ |
| 72 | 2014 | Dale B. Schenk, Ph.D. Former President and Chief Executive Officer | 491.7K | — | — | 2.23M | 295.0K | 11.7K | 3.03M | 73.61% | ↗ |
| 73 | 2014 | Dale B. Schenk, Ph.D. President and Chief Executive Officer | 491.7K | — | — | 2.23M | 295.0K | 11.7K | 3.03M | 73.61% | ↗ |
| 74 | 2014 | Martin Koller, M.D. Chief Medical Officer | 348.5K | — | — | 1.52M | 141.1K | 11.7K | 2.02M | 75.19% | ↗ |
| 75 | 2014 | Martin Koller, M.D. Chief Medical Officer | 348.5K | — | — | 1.52M | 141.1K | 11.7K | 2.02M | 75.19% | ↗ |
| 76 | 2014 | A. W. Homan Chief Legal Officer | 217.9K | — | — | 1.60M | 85.0K | 9.9K | 1.92M | 83.68% | ↗ |
| 77 | 2014 | A. W. Homan Chief Legal Officer | 217.9K | — | — | 1.60M | 85.0K | 9.9K | 1.92M | 83.68% | ↗ |
| 78 | 2014 | Gene G. Kinney, Ph.D. Chief Scientific Officer and Head of Research and Development | 348.3K | 50.0K | — | 954.4K | 148.0K | 11.7K | 1.51M | 63.10% | ↗ |
| 79 | 2014 | Gene G. Kinney, Ph.D. Chief Scientific Officer and Head of Research and Development | 348.3K | 50.0K | — | 954.4K | 148.0K | 11.7K | 1.51M | 63.10% | ↗ |
| 80 | 2014 | Gene G. Kinney, Ph.D. President and Chief Executive Officer | 348.3K | 50.0K | — | 954.4K | 148.0K | 11.7K | 1.51M | 63.10% | ↗ |
| 81 | 2014 | Tran B. Nguyen Chief Financial Officer | 338.3K | — | — | 954.4K | 140.4K | 14.0K | 1.45M | 65.95% | ↗ |
| 82 | 2014 | Tran B. Nguyen Chief Financial Officer | 338.3K | — | — | 954.4K | 140.4K | 14.0K | 1.45M | 65.95% | ↗ |
| 83 | 2013 | Dale B. Schenk, Ph. D. President and Chief Executive Officer | 462.1K | — | — | 1.95M | 351.0K | 16.4K | 2.78M | 70.21% | ↗ |
| 84 | 2013 | Dale B. Schenk, Ph.D. President and Chief Executive Officer | 462.1K | — | — | 1.95M | 351.0K | 12.8K | 2.78M | 70.30% | ↗ |
| 85 | 2013 | Dale B. Schenk, Ph.D. President and Chief Executive Officer | 462.1K | — | — | 1.95M | 351.0K | 12.8K | 2.78M | 70.30% | ↗ |
| 86 | 2013 | Tran B. Nguyen Chief Financial Officer | 253.8K | 25.0K | — | 865.1K | 171.6K | 220.0K | 1.54M | 56.34% | ↗ |
| 87 | 2013 | Tran B. Nguyen Chief Financial Officer | 253.8K | 25.0K | — | 865.1K | 171.6K | 220.0K | 1.54M | 56.34% | ↗ |
| 88 | 2013 | Gene Kinney, Ph. D. Chief Scientific Officer and Head of Research and Development | 349.2K | — | — | 857.6K | 176.8K | 13.9K | 1.40M | 61.37% | ↗ |
| 89 | 2013 | Gene G. Kinney, Ph.D. Chief Scientific Officer and Head of Research and Development | 349.2K | — | — | 857.6K | 176.8K | 12.8K | 1.40M | 61.42% | ↗ |
| 90 | 2013 | Gene G. Kinney, Ph.D. Chief Scientific Officer and Head of Research and Development | 349.2K | — | — | 857.6K | 176.8K | 12.8K | 1.40M | 61.42% | ↗ |
| 91 | 2013 | Martin Koller, M.D. Chief Medical Officer | 230.2K | — | — | 600.8K | 119.7K | 7.0K | 957.6K | 62.74% | ↗ |
| 92 | 2013 | Martin Koller, M.D. Chief Medical Officer | 230.2K | — | — | 600.8K | 119.7K | 7.0K | 957.6K | 62.74% | ↗ |
| 93 | 2013 | A. W. Homan Chief Legal Officer | — | — | — | — | — | — | — | — | ↗ |
| 94 | 2012 | Dale B. Schenk, Ph.D. President and Chief Executive Officer | 477.9K | — | 600.0K | 1.10M | 287.4K | 100.8K | 2.57M | 66.25% | ↗ |
| 95 | 2012 | Dale B. Schenk, Ph. D. President and Chief Executive Officer | 477.9K | — | 600.0K | 1.10M | 287.4K | 100.8K | 2.57M | 66.25% | ↗ |
| 96 | 2012 | Gene Kinney, Ph.D. Chief Scientific Officer and Head of Research Development | 215.9K | — | 462.5K | 862.7K | 88.3K | 15.2K | 1.64M | 80.58% | ↗ |
| 97 | 2012 | Gene Kinney, Ph. D. Chief Scientific Officer and Head of Research and Development | 215.9K | — | 462.5K | 862.7K | 88.3K | 15.2K | 1.64M | 80.58% | ↗ |
| 98 | 2012 | Tara Nickerson, Ph.D. Head of Corporate Business Development | 265.3K | — | 200.0K | 150.0K | 91.2K | 37.6K | 744.1K | 47.04% | ↗ |
| 99 | 2011 | Dale B. Schenk, Ph. D. President and Chief Executive Officer | 449.4K | 95.5K | 275.0K | 822.4K | 404.5K | 15.8K | 2.06M | 53.20% | ↗ |
| 100 | 2011 | Dale B. Schenk, Ph.D. President and Chief Executive Officer | 449.4K | — | 275.0K | 822.4K | 500.0K | 15.8K | 2.06M | 53.20% | ↗ |
| 101 | 2011 | Gene Kinney, Ph. D. Chief Scientific Officer and Head of Research and Development | 176.0K | 100.1K | 300.0K | 800.0K | 99.9K | 26.0K | 1.50M | 73.24% | ↗ |
| 102 | 2011 | Gene Kinney, Ph.D. Chief Scientific Officer and Head of Research Development | 176.0K | — | 300.0K | 800.0K | 200.0K | 26.0K | 1.50M | 73.24% | ↗ |
| 103 | 2011 | Tara Nickerson, Ph.D. Head of Corporate Business Development | 221.3K | — | 176.0K | — | 125.0K | 5.2K | 527.5K | 33.36% | ↗ |
| 104 | 2010 | Dale B. Schenk, Ph.D. President and Chief Executive Officer | 376.2K | — | 300.0K | 295.8K | 320.0K | 16.3K | 1.31M | 45.54% | ↗ |
| 105 | 2010 | Gene Kinney, Ph.D. Chief Scientific Officer and Head of Research Development | 162.6K | — | 250.0K | — | 75.0K | 31.4K | 519.0K | 48.17% | ↗ |
| 106 | 2010 | Tara Nickerson, Ph.D. Head of Corporate Business Development | 207.3K | — | 75.0K | — | 75.0K | 3.7K | 361.0K | 20.78% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gene G. Kinney | President, Chief Executive Officer & Director | 1M | — |
| Tran Nguyen | Chief Financial Officer | 916.3K | male |
| Brandon S. Smith | Chief Operating Officer | 826.8K | male |
| Chad Swanson | Chief Development Officer | 739.1K | — |
| Wagner Zago | Chief Scientific Officer | 735.7K | — |
| Michael J. Malecek | Chief Legal Officer & Company Secretary | 588.3K | male |
| Mark C. Johnson | Vice President of Investor Relations | — | male |
| Karin L. Walker | Chief Accounting Officer & Controller | — | female |
| Annie Evans Kingston | Chief Strategy Officer | — | female |
| Phillip Dolan | Sr. Director & Head of Exploratory Research | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PRTA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
